“Think globally, act locally” may be an old saw, but in the context of today’s supply chain chaos, it retains timeless business wisdom. It occurred to me as I read an announcement from contract medical technology manufacturer Phillips-Medisize regarding an expansion of its global manufacturing footprint. The company’s global reach currently encompasses 36 production plants, and while offshoring is part of the business model, it’s also true that this constellation of facilities serves the mission of meeting localized demand.

Commenting on the company’s focus on providing its customers with end-to-end capabilities, no matter where they are located, Paul Chaffin, president of medical and pharmaceutical solutions at Molex, the parent company of Phillips-Medisize, said : “As a preferred partner to major global customers, we continually invest in new talent and technologies that increase Phillips-Medisize’s capacity and capabilities across the value chain. Our expanded global reach and resources will allow us to solve complex development and manufacturing challenges while meeting growing customer demands for more localized production, supply chain management and accelerated time-to-market strategies. . “

On that note, Phillips-Medisize is building a state-of-the-art medical manufacturing facility in Katowice, Poland. The site is scheduled to open in 2022, the site will complement production sites and innovation centers in Asia, Europe, India, Mexico and North America, according to the announcement. Phillips-Medisize is also expanding its production capacity in Suzhou, China to serve global and regional pharmaceutical and medical customers. Here in the United States, an existing Molex production facility in Little Rock, AR, is being renovated to allow Phillips-Medisize to “keep pace with [domestic] requirements for the manufacture of high volume diagnostic devices.

Once these expansions are complete, Phillips-Medisize said it will offer nearly three million square feet (280,000 square meters) of manufacturing space and R&D capabilities specific to each country and region around the world. The company will also support 600,000 square feet / 55,000 square meters of Class 7 and 8 cleanrooms, which complement existing tool construction sites as well as global quality and regulatory systems. In 2020, Phillips-Medisize completed a new facility in St. Croix Meadows, WI, with 285,000 square feet (26,000 square meters) supporting the production of molded components for medical diagnostic customers. This facility also includes an ISO 14644-1 certified Class 8 cleanroom of nearly 64,000 square feet (6,000 square meters).

A self-proclaimed one-stop-shop for medical device manufacturing, Phillips-Medisize focuses on design for manufacturing and assembly expertise, he said in the announcement. Extensive capabilities in complex molding, drug and reagent handling, as well as final packaging and serialization, enable customers to consolidate global supply chains while optimizing go-to-market strategies, added the society.

Phillips-Medisize’s combined expertise in plastics, metals, electronics and connectivity facilitates the design and manufacture of combination devices, such as needle injection systems and portable injection technologies.

Phillips-Medisize was acquired by Molex in 2016, which brought its electronics expertise and global reach into the fold. At the time of the acquisition, Matt Jennings, Chairman, President and CEO of Phillips-Medisize, said: “Molex’s global reach in electronics, coupled with the strength of Phillips- Medisize in the design and manufacture of innovative products for medical device customers, will help us become a global leader in connected health solutions.

Indeed, in the press release released yesterday, Phillips-Medisize announced a strategic initiative with Credence MedSystems. The agreement will support the scale-up of the manufacturing of the Credence Companion and dual chamber replenishment systems. Other potential areas of collaboration include auto-injectors and connectivity products, said Credence MedSystems. The Credence Connect Automatically Sensing Injection System is a connected syringe device targeting chronic disease management and enabling better clinical trial compliance. “We are excited to take advantage of Phillips-Medisize’s world-class manufacturing as we move towards high-volume automation at the new state-of-the-art facility in Poland,” said Jeff Tillack, COO at Credence MedSystems. “The ability to increase production close to our operations and to our European customers will accelerate the time to market of our innovative solutions to meet the needs of our pharmaceutical customers and their end users. “

Other recent agreements include a design and development program with GlucoModicum for the rapid scale-up of manufacturing of its Talisman needle-free continuous glucose monitor and an agreement with Paris-based Eyevensys to optimize the design, development and production. high volume manufacture of its ocular device component that feeds the delivery of novel gene therapies for the treatment of various eye diseases.

On average, Phillips-Medisize said it markets 50 new products per year for its customers, including the first FDA-registered drug delivery device using a connected health system.